Related Experiment Video
Updated: Feb 17, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.6K
GDSCTools for mining pharmacogenomic interactions in cancer
Thomas Cokelaer1, Elisabeth Chen2, Francesco Iorio3
1Institut Pasteur-Bioinformatics and Biostatistics Hub-C3BI, USR 3756 IP CNRS, Paris, France.
Bioinformatics (Oxford, England)
|November 30, 2017
Summary
GDSCTools software aids in identifying cancer genomic markers for drug response. It integrates diverse datasets, enabling researchers to discover new cancer therapies by analyzing drug sensitivity and genomic features.
Area of Science:
- Computational Biology
- Pharmacogenomics
- Cancer Research
Background:
- Large-scale pharmacogenomic screenings generate vast amounts of heterogeneous cancer genomic data and anti-cancer drug responses.
- Analyzing this data is crucial for identifying novel therapies for specific cancer subpopulations.
- Common data structures, modular computational tools, and user-friendly interfaces are needed for effective data mining.
Purpose of the Study:
- To develop GDSCTools, a software package for identifying clinically relevant genomic markers of drug response.
- To facilitate the analysis of the Genomics of Drug Sensitivity in Cancer (GDSC) database and other pharmacogenomic datasets.
- To enable researchers to reproduce existing findings and implement new analytical methods.
Main Methods:
- GDSCTools integrates heterogeneous cancer genomic datasets and anti-cancer drug responses.
- It incorporates statistical tools such as analysis of variance (ANOVA).
- Predictive methods like Elastic Net are included for data analysis.
- The software supports common data structures and allows analysis of non-GDSC data via CSV files.
Main Results:
- GDSCTools enables the identification of clinically relevant genomic markers associated with drug response.
- Users can reproduce published results from the GDSC database.
- New analytical methods for pharmacogenomic data can be implemented using the software.
- The tool facilitates the analysis of both GDSC and external datasets.
Conclusions:
- GDSCTools provides a valuable computational resource for pharmacogenomic research.
- It supports the integration and analysis of diverse cancer genomic and drug response data.
- The software empowers researchers to discover new therapeutic strategies and biomarkers for cancer treatment.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
10
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
10
01:11Genome-wide Association Studies-GWAS
15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.8K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
01:29Pharmacogenetics and Pharmacogenomics: Overview
13
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
13
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18